• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-p63 antibody :: Rabbit p63 Monoclonal Antibody

Scan QR to view Datasheet
Catalog # MBS684194
Unit / Price
  1 mL (Prediluted)  /  $175 +1 FREE 8GB USB
  0.04 mL (Concentrate)  /  $185 +1 FREE 8GB USB
  0.1 mL (Concentrate)  /  $325 +1 FREE 8GB USB
  7 mL (Prediluted)  /  $340 +1 FREE 8GB USB
  0.2 mL (Concentrate)  /  $420 +1 FREE 8GB USB
  15 mL (Prediluted)  /  $490 +1 FREE 8GB USB
  0.5 mL (Concentrate)  /  $530 +1 FREE 8GB USB
  1 mL (Concentrate)  /  $805 +1 FREE 8GB USB
Product Name

p63, Monoclonal Antibody

Popular Item
Full Product Name

Anti - p63

Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Chromosome Location
Chromosome: 3; NC_000003.12 (189631160..189897279). Location: 3q28
OMIM
103285
3D Structure
ModBase 3D Structure for Q9H3D4
Clonality
Monoclonal
Clone Number
I27-I
Host
Rabbit
Specificity
Human
Immunogen
Peptide derived from the internal sequence of human p63. Antibody recognizes the epitope between Arg360-His383.
Storage Buffer
20 mM Tris-HCI, pH 8.0
Stabilizer
20 mg/ml BSA
Preservative
0.05% NaN3
IHC-P PROTOCOL
1.Deparaffinize the section in 3 changes of xylene, 5 minutes each.
2.Wash the section in 96%, 80% and 0% thyl alcohol for 10 minutes each. .
3.Rinse in distilled water. .
4.Block the endogenous peroxidase by incubating the tissuein 3% hydrogen peroxide (H2O2) for 10 minutes. .
5.Wash in distilled water for 5 minutes. .
6.For antigen retrieval: immerse the slide in the citrate buffer, pH 6.0, 0.05% Tween-20*, and incubate in ater bath at 96°C for 40 minutes. (Alternatively adjust to your own protocol, keeping the required pH) .
7.Remove the staining to room temperature and let the slide to cool (in citrate buffer, pH 6.0) for 20 minutes. .
8.Rinse in distilled water. .
9.Wash in 0.05 M Tris-HCl, pH 7.6 buffer supplemented with 0.2% of Tween-20 (buffer A) for 5 minutes.
10.CONCENTRATED:Incubate the section with primary antibody at the dilution 1:100 -1:200 for 1 hour in the closed wet chamber. .
.READY TO USE (RTU):Incubate the section with primary antibody (ready to use)for 1 hour in a closed wet chamber.
11.Wash twice 5 minutes with buffer A. .
12.Apply the secondary antibody (the protocol depends on the supplier), and proceed to standard immunohistochemistry protocol (HRP -Peroxide -DAB). Micropolymer-HRP detection kit rabbit/mouse .
13.Wash twice 5 minutes with buffer A. .
14.Apply the chromogen (DAB), 1 -3 minutes. .
15.Wash in water for 10 minutes. .
16.Stain in hematoxylin for 5 minutes. .
17.Wash in water for 10 minutes. .
18.Dehydrate the section in 2 changes of 96% ethyl alcohol for 5 minutes each.
19.Wash the section in 2 changes of xylene for 2 minutes each. .
20.Mount the slide for observation.


Citrate Buffer(10mM Citric Acid, 0.05% Tween-20, pH 6.0):
Citric acid (anhydrous) ----------1.92 g; Distilled water ---------1000 ml.
Mix to dissolve in 700 ml of distilled water. Adjust pH to 6.0 with 1M NaOH and then add 0.5 ml of Tween-20 and mix well.
Adjust the final volume to 1 liter with distilled water.

Store this solution at room temperature for 3 months or at +4°C for longer storage.
PRECAUTIONS
1.-We strongly recommend to use Primary Antibody Diluent eventually alternative diluent containing protease free BSA at the concentrations ? 1mg/ml) for dilution of concentrated antibodies, otherwise the warranty might be voided.
2.Centrifuge the vial before use.
3.Intended for professional In Vitro Diagnostic use in laboratories. .
4.Do not use after expiration date stamped on vial label. .
5.Avoid contamination of the reagent. .
6.Any discrepancies in the recommended procedures stated in the working protocol may affect the final results. .
7.The reagent contains sodium azide (NaN3) which is highly toxic in higher concentrations. The concentration in the reagent (0.05%) is not considered as hazardous. .
8.Disposal of waste material must be conducted in accordance with local regulations. .
9.Wear appropriate Personal Protective Equipment to avoid contact with eyes and skin.
VENTANA PROTOCOL INSTRUCTION MANUAL
SHORT APPLICATION PROTOCOL FOR VENTANA BENCHMARK SLIDE STAINING SYSTEM

1.-Deparafinization (Enter)
2.Heating glass (72°C) with the medium temperatures. Deparafinization.
3.Prolonged deparafinization (Enter).
4.Cell conditioning (Enter)
.5.ULTRA Conditioner #2 (Enter).
6.Heating glass (97°C), incubation 8 min (Cell conditioner #2).
7.ULTRA CC2 solution application –24 min (Enter).
8.Titration (Enter).
9.Hand apply –primary antibody. Incubation 32 min.
10.UltraWash (Enter).
11.Nuclear stain (Enter).
12.Hematoxylin application –one drop (nuclear stain). Cover and incubate 8 min.
13.After nuclear stain (Enter).
14.Bluing reagent application, one drop. After nuclear stain, cover and incubate 4 min
.
Preparation and Storage
Store at +4°C.
ISO Certification
Manufactured in an ISO 9001:2008 and ISO 13485:2003 Certified Laboratory.
Other Notes
Small volumes of anti-p63 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-p63 antibody
Immunohistochemistry (IHC) - Formalin/Paraffin
Application Notes for anti-p63 antibody
IHC-P dilution ready to use.

Testing Data of anti-p63 antibody
Nuclear expression of p63 visualized with MBS684194, anti-p63 antibody, clone I27-I; in normal hair follicles (A)basal cell carcinoma of the skin.
anti-p63 antibody Testing Data image
Testing Data #2 of anti-p63 antibody
Nuclear expression of p63 visualized with MBS684194, anti-p63 antibody, clone I27-I; in normal hair follicles (B)squamous epithelium of the tonsil
anti-p63 antibody Testing Data #2 image
Testing Data #3 of anti-p63 antibody
Nuclear expression of p63 visualized with MBS684194, anti-p63 antibody, clone I27-I; in normal hair follicles (C) and basal cells of the prostatic glands.
anti-p63 antibody Testing Data #3 image
Testing Data #4 of anti-p63 antibody
Nuclear expression of p63 visualized with MBS684194, anti-p63 antibody, clone I27-I; in normal hair follicles (D) Formalin fixed, paraffin embedded human tissues (4um sections) stained with anti-p63 (MBS684194) monospecific clonal antibody according to related datasheet.
anti-p63 antibody Testing Data #4 image
NCBI/Uniprot data below describe general gene information for p63. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
Tumor protein 63
NCBI Official Synonym Full Names
tumor protein p63
NCBI Official Symbol
NCBI Official Synonym Symbols
AIS; KET; LMS; NBP; RHS; p40; p51; p63; EEC3; OFC8; p73H; p73L; SHFM4; TP53L; TP73L; p53CP; TP53CP; B(p51A); B(p51B)
  [Similar Products]
NCBI Protein Information
tumor protein 63; CUSP; transformation-related protein 63; tumor protein p53-competing protein; amplified in squamous cell carcinoma; chronic ulcerative stomatitis protein; keratinocyte transcription factor KET; tumor protein p63 deltaN isoform delta
UniProt Protein Name
Tumor protein 63
UniProt Synonym Protein Names
Chronic ulcerative stomatitis protein; CUSP; Keratinocyte transcription factor KET; Transformation-related protein 63; TP63; Tumor protein p73-like; p73L; p40; p51
UniProt Gene Name
UniProt Synonym Gene Names
KET; P63; P73H; P73L; TP73L; p63; CUSP; TP63; p73L  [Similar Products]
UniProt Entry Name
P63_HUMAN
NCBI Summary for p63
This gene encodes a member of the p53 family of transcription factors. An animal model, p63 -/- mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 -/- mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); split-hand/foot malformation 4 (SHFM4); ankyloblepharon-ectodermal defects-cleft lip/palate; ADULT syndrome (acro-dermato-ungual-lacrimal-tooth); limb-mammary syndrome; Rap-Hodgkin syndrome (RHS); and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. [provided by RefSeq, Jul 2008]
UniProt Comments for p63
Function: Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specificactivity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter. Ref.3 Ref.15 Ref.17 Ref.18 Ref.19 Ref.23 Ref.24

Cofactor: Binds 1 zinc ion per subunit

By similarity.

Subunit structure: Binds DNA as a homotetramer. Isoform compositionof the tetramer may determine transactivation activity. Isoforms Alpha and Gamma interact with HIPK2. Interacts with SSRP1, leading to stimulate coactivator activity. Isoform 1 and isoform 2 interact with WWP1. Interacts with PDS5A. Isoform 5 (via activation domain) interacts with NOC2L. Ref.10 Ref.13 Ref.16 Ref.19 Ref.21 Ref.22 Ref.23

Subcellular location: Nucleus Ref.17 Ref.23.

Tissue specificity: Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform variesaccording to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues. Ref.3 Ref.8 Ref.14

Domain: The transactivation inhibitory domain (TID) can interact with, and inhibit the activity of the N-terminal transcriptional activation domain of TA*-type isoforms. Ref.17 Ref.18

Post-translational modification: May be sumoylated

By similarity.Ubiquitinated. Polyubiquitination involves WWP1 and leads to proteasomal degradation of this protein. Ref.21

Involvement in disease: Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome) [MIM:103285]: A form of ectodermal dysplasia. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. ADULT syndrome involves ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic breasts and nipples, intensive freckling, lacrimal duct atresia, frontal alopecia, primary hypodontia and loss of permanent teeth. ADULT syndrome differs significantly from EEC3 syndrome by the absence of facial clefting.Note: The disease is caused by mutations affecting the gene represented in this entry.Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) [MIM:106260]: An autosomal dominant condition characterized by congenital ectodermal dysplasia with coarse, wiry, sparse hair, dystrophic nails, slight hypohidrosis, scalp infections, ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia and cleft lip/palate.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.29Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3) [MIM:604292]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. It is an autosomal dominant syndrome characterized by ectrodactyly of hands and feet, ectodermal dysplasia and facial clefting.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.26 Ref.27 Ref.30 Ref.32Split-hand/foot malformation 4 (SHFM4) [MIM:605289]: A limb malformation involving the central rays of the autopod and presenting with syndactyly, median clefts of the hands and feet, and aplasia and/or hypoplasia of the phalanges, metacarpals, and metatarsals. Some patients have been found to have mental retardation, ectodermal and craniofacial findings, and orofacial clefting.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.27 Ref.30Limb-mammary syndrome (LMS) [MIM:603543]: Characterized by ectrodactyly, cleft palate and mammary-gland abnormalities.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.30Defects in TP63 are a cause of cervical, colon, head and neck, lung and ovarian cancers.Ectodermal dysplasia, Rapp-Hodgkin type (EDRH) [MIM:129400]: A form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Characterized by the combination of anhidrotic ectodermal dysplasia, cleft lip, and cleft palate. The clinical syndrome is comprised of a characteristic facies (narrow nose and small mouth), wiry, slow-growing, and uncombable hair, sparse eyelashes and eyebrows, obstructed lacrimal puncta/epiphora, bilateral stenosis of external auditory canals, microsomia, hypodontia, cone-shaped incisors, enamel hypoplasia, dystrophic nails, and cleft lip/cleft palate.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.33 Ref.34 Ref.35 Ref.36Non-syndromic orofacial cleft 8 (OFC8) [MIM:129400]: A birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum.Note: The disease is caused by mutations affecting the gene represented in this entry.

Sequence similarities: Belongs to the p53 family.Contains 1 SAM (sterile alpha motif) domain.

Sequence caution: The sequence AAF43486.1 differs from that shown. Reason: Erroneous initiation. The sequence AAF43487.1 differs from that shown. Reason: Erroneous initiation. The sequence AAF43488.1 differs from that shown. Reason: Erroneous initiation. The sequence AAF43489.1 differs from that shown. Reason: Erroneous initiation. The sequence AAF61624.1 differs from that shown. Reason: Frameshift at position 26. The sequence BAA32592.1 differs from that shown. Reason: Frameshift at position 26. The sequence BAA32593.1 differs from that shown. Reason: Frameshift at position 26.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000